ESR1 and breast carcinoma: Intriguingly, it has been a longstanding conundrum in the field that ER+ breast cancer xenografts grown in mice do not regress in response to tamoxifen (39–41), a phenomenon that is otherwise commonly being observed in patient tumors exposed to neoadjuvant tamoxifen (37).